What "Small Diabetes Risk" Means with Statin Therapy
When we say statins carry a "small diabetes risk," we mean that statin therapy causes approximately one additional case of new-onset diabetes for every 255 patients treated over 4 years—a modest absolute increase that is vastly outweighed by the cardiovascular benefits. 1, 2
Understanding the Numbers
The diabetes risk from statins breaks down as follows:
- Low-to-moderate intensity statins: 10% relative increase in new-onset diabetes compared to placebo 1
- High-intensity statins: 36% relative increase compared to placebo 1
- Absolute risk: One extra diabetes case per 255 patients treated for 4 years 3, 4, 2
This translates to a 9-12% increased relative risk in clinical trials, though population-based studies have reported higher rates (18-99%) 5. The discrepancy exists because diabetes wasn't a prespecified endpoint in most statin trials, and glucose/HbA1c weren't routinely measured, likely underestimating the true incidence 5.
Why It's Considered "Small"
The Glycemic Changes Are Minimal
Statins produce only a small increase in blood glucose levels—the mean weight gain associated with statin therapy is just 0.30 kg, far too small to explain the diabetes risk through weight gain alone 1. Each year of statin therapy, a new group of people becomes at risk of crossing the diagnostic threshold for diabetes due to age-related increases in blood sugar, and those on statins are only slightly more likely to do so 1.
The Cardiovascular Benefits Dwarf the Diabetes Risk
The cardiovascular benefits of statin therapy represent the net effect of all statin actions, including any theoretical adverse effects from increased glycemia—meaning the diabetes risk is already factored into the observed cardiovascular benefit. 1 The JUPITER trial demonstrated that cardiovascular benefits of rosuvastatin greatly outweighed diabetes risks even in primary prevention among apparently healthy people 1.
Importantly, the risk of future major vascular events following a heart attack or stroke is significantly greater than the risk following a diabetes diagnosis 1. The USPSTF found that statin benefits clearly outweigh the small diabetes risk in adults aged 40-75 with cardiovascular risk factors 6.
Clinical Context
Who Is at Higher Risk
The absolute excess of new-onset diabetes is highest among individuals whose glucose levels are already close to the diagnostic threshold for diabetes 1. Patients with prediabetes, obesity, or other metabolic risk factors face greater risk 7.
Differences Between Statins
Not all statins carry equal diabetes risk:
- Least diabetogenic: Pravastatin and pitavastatin 5, 7
- Most diabetogenic: Simvastatin, atorvastatin, and rosuvastatin 5, 7
High-intensity statins like atorvastatin and rosuvastatin carry greater risk than moderate-intensity options 7.
The Risk Persists But Doesn't Worsen Over Time
The relative risk remains consistent while treatment continues 1. However, among people who already have diabetes at baseline, the early excess of worsening glycemic control with statins does not persist long-term, likely because glucose is monitored and managed in these individuals 1.
Bottom Line for Practice
Clinical practice should not change based on this small diabetes risk. 2 The term "small" reflects both the modest absolute increase (1 in 255 patients over 4 years) and the fact that this risk is negligible compared to the substantial reduction in heart attacks, strokes, and cardiovascular death that statins provide. Any theoretical cardiovascular harm from the slight glucose elevation is already accounted for in the net cardiovascular benefit observed in trials 1.